CARsgen Therapeutics Holdings Ltd
HKEX:2171

Watchlist Manager
CARsgen Therapeutics Holdings Ltd Logo
CARsgen Therapeutics Holdings Ltd
HKEX:2171
Watchlist
Price: 15.26 HKD -0.91% Market Closed
Market Cap: 8.7B HKD

Gross Margin
CARsgen Therapeutics Holdings Ltd

37.4%
Current
23%
Average
63.9%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
37.4%
=
Gross Profit
14.7m
/
Revenue
39.4m

Gross Margin Across Competitors

CARsgen Therapeutics Holdings Ltd
Glance View

Market Cap
8.7B HKD
Industry
Biotechnology

CARsgen Therapeutics Holdings Ltd. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of CAR-T cell therapies. The company is headquartered in Shanghai, Shanghai and currently employs 573 full-time employees. The company went IPO on 2021-06-18. The Company’s therapies are applied in the treatment of hematological malignancies and solid tumors. The firm have developed an upgraded B cell maturation antigen (BCMA) targeted CAR-T product, CT053, which is its sole core product candidate. The firm conducts its businesses in China and the United States.

Intrinsic Value
9.32 HKD
Overvaluation 39%
Intrinsic Value
Price
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
37.4%
=
Gross Profit
14.7m
/
Revenue
39.4m
What is the Gross Margin of CARsgen Therapeutics Holdings Ltd?

Based on CARsgen Therapeutics Holdings Ltd's most recent financial statements, the company has Gross Margin of 37.4%.

Back to Top